Developer docs
API playgroundTry for free, no card

Search company profiles

Qidni Labs

Full company profile

uuid0003bem

Namestring
Qidni Labs
Legal namestring
Qidni Labs Inc.
Websiteurl
qidni.life
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Qidni Labs Inc. is a privately held medical device company developing portable, infrastructure-independent hemodialysis technology. Founded in 2014 and headquartered across Buffalo, New York and Kitchener, Ontario, the company is led by founder and CEO Morteza Ahmadi and operates with fewer than 10 employees. Its stated objective is to address the up to 10 million kidney failure patients globally who lack access to dialysis, and its technology is targeted at rural populations, home dialysis candidates rejected due to inadequate water or electrical infrastructure, disaster response settings, satellite clinics, pandemic scenarios, and military or battlefield medical use.

The company's product platform is built around Qartridge™, a proprietary selective-absorption cartridge that removes uremic toxins and other solutes directly from whole blood, eliminating the need for the approximately 120 liters of dialysate and 300–500 liters of purified water required by conventional hemodialysis. The flagship device, Qidni/D, integrates this cartridge into one of the most miniaturized dialysis machines ever built, offering rechargeable battery operation, 3–4 hour treatment times comparable to standard hemodialysis, and cloud-based remote monitoring by the clinical team. Qartridge™ is positioned as a platform technology with stated optionality for selective removal of other solutes and biofluids beyond kidney applications.

Commercially, Qidni is pre-revenue: the company's own website states that Qidni devices and Qartridges are not approved by the US FDA or Health Canada and are not available for commercial sale. The intended revenue model combines hardware sales of the Qidni/D device, recurring revenue from single-use Qartridge™ consumables priced comparably to existing hemodialysis consumables, and licensing or partnership income from the underlying platform technology. The company has been financed through a mix of equity (SOSV/IndieBio, 43North, Sunhope Capital, ECO Angels/ECOAST Angels, China Canada Angel Alliance, Velocity) and non-dilutive capital (NRC IRAP, OBIO BDSP, L-SPARK, NATO DIANA), and is actively soliciting licensing and distribution partners as its primary go-to-market pathway.

Short descriptiontext

Qidni Labs Inc. is a pre-commercial medical device company developing Qartridge™, a proprietary selective-absorption cartridge, and the Qidni/D portable dialysis machine that performs hemodialysis without dialysate, purified water, or grid power, targeting the global population of kidney failure patients without access to conventional dialysis infrastructure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBuffalo, United States
HQ citystring
Buffalo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
portable dialysis devices, hemodialysis technology, medical device cartridges, kidney replacement therapy, blood purification systems
Industry3 codes
PRIMARYHLAHAKAA
Hemodialysis Machines & Systems
SECONDARYHLAHAKAH
Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges)
SECONDARYHLAHAKAG
Home Dialysis Equipment & Remote Monitoring
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices — Dialysis Equipment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Qartridge™ Consumables
TypeHardware Sales
Description

The Qartridge™ (Qidni cartridge) is a single-use disposable component for each dialysis session. Cost per treatment session is similar to current hemodialysis consumables cost. The company emphasizes they do not use expensive exotic materials in their cartridges.

qidni.life
2Qidni/D Device Sales
TypeHardware Sales
Description

The Qidni/D flagship portable dialysis machine will be sold as a device. The company is pursuing licensing and partnership opportunities for distribution.

qidni.life
3Technology Licensing
TypeLicensing Royalties
Description

The company is seeking licensing and partnership opportunities for their platform technology, which can be modified for applications beyond kidney dialysis for selective removal of target solutes from whole blood and other biofluids.

qidni.life
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Qartridge™
Description

Proprietary platform technology providing high capacity for selective absorption and removal of uremic toxins and other solutes from large volumes of whole blood. The first application is in kidney blood dialysis.

qidni.life
Core offering1 text field

Qidni Labs develops and plans to commercialize a portable, infrastructure-independent hemodialysis system comprising the Qidni/D miniaturized dialysis machine and the single-use Qartridge™ consumable. The system removes uremic toxins from whole blood without requiring dialysate, purified tap water, or AC power, enabling dialysis in rural areas, homes, disaster zones, battlefields, and satellite clinics while treatments are monitored remotely through a cloud-based clinical platform. The company is pre-commercial, pursuing FDA/Health Canada approval and actively seeking licensing and distribution partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Water savings of 300-500L per treatment (equivalent to average person's daily water usage)
+2 more records
Product overview1 text field

Qidni Labs offers a unified product portfolio centered on portable, accessible dialysis technology. The flagship product Qidni/D is a miniaturized dialysis machine that eliminates traditional infrastructure dependencies (no dialysate, no tap water, no electrical outlet required). This is powered by Qartridge™ technology, a proprietary selective blood purification cartridge that removes uremic toxins without the 120L of purified water needed in conventional hemodialysis. Together, these products enable dialysis in rural areas, disaster settings, military/battlefield environments, ambulances, satellite clinics, and homes where water and electricity infrastructure is unreliable or unavailable.

Product and service2 records
1Qartridge™
CategoryDialysis consumables / Cartridges
Description

Qartridge™ (Qidni cartridge) is a proprietary single-use disposable cartridge that provides high-capacity selective absorption and removal of uremic toxins and other solutes from large volumes of whole blood without requiring dialysate or large quantities of purified water. It is intended for use with the Qidni/D device to enable dialysis in settings where conventional water and dialysate infrastructure is unavailable, and the platform is also licensable for selective removal of target solutes from whole blood and other biofluids.

2Qidni/D
CategoryHemodialysis machines / Medical devices
Description

Qidni/D is a miniaturized, portable hemodialysis machine designed to function as a "dialysis clinic in a dialysis machine." It operates without dialysate, tap water, water purification systems, or AC power (can run on rechargeable batteries), delivers 3–4 hour treatment sessions comparable to existing hemodialysis, and is monitored remotely by the clinical team via a cloud-based system. It targets use in rural areas, homes, satellite clinics, ambulances, disaster response, and military/battlefield settings.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

JATEC selected Qidni Labs as one of nine companies to develop AI-based counter-drone solutions, medical systems, and autonomous defence technologies. JATEC is the first partner organization within NATO's structure with Ukraine holding equal status to member states. Based in Bydgoszcz, Poland.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Qidni Labs won first place in NATO's 17th Innovation Challenge focused on battlefield medical innovation. Winners will advance toward rapid prototyping and field testing with Allied forces. NATO is prioritizing layered resilience and medical readiness adapted to drone surveillance, jamming, and extended evacuation delays.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on Qidni Labs' Funding page. Ontario-based innovation organization supporting technology development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on Qidni Labs' Funding page. Canadian government research organization supporting R&D.

5Canada Space Agency (ASC-CSA)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on Qidni Labs' Funding page.

qidni.life
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on Qidni Labs' Funding page. Toronto-based innovation hub supporting startups.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on Qidni Labs' Funding page. Canadian accelerator for technology companies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on Qidni Labs' Funding page. A public-private partnership to accelerate innovation in kidney care.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on Qidni Labs' Funding page. Canadian federal research funding agency.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

US-based developer of a portable hemodialysis system for home and acute care settings. Competes in the same miniaturized hemodialysis category as Qidni/D.

TypeBroad incumbent
Description

Diversified medtech incumbent with renal care exposure and adjacent therapeutic apheresis technology. Relevant as a potential strategic acquirer given Qartridge's platform applicability beyond dialysis.

TypeDirect peer
Description

Developer of Tablo, an FDA-cleared portable/home hemodialysis system with water purification and intuitive UX. Most directly comparable device competitor to Qidni/D in miniaturized dialysis for home and clinic settings.

TypeBroad incumbent
Description

Global leader in dialysis products and services (owns NxStage). Operates thousands of dialysis clinics and manufactures machines, dialyzers, and consumables — the dominant incumbent Qidni must eventually compete with or partner into.

TypeBroad incumbent
Description

Pioneer in home hemodialysis (NxStage System One), now owned by Fresenius. Most analogous precedent for portable home hemodialysis market entry — useful comparator for Qidni's regulatory and adoption trajectory.

TypeBroad incumbent
Description

Largest US dialysis services provider operating thousands of outpatient clinics. Relevant for downstream channel access, payer relationships, and as a potential acquirer/licensor of portable dialysis innovations.

TypeBroad incumbent
Description

Major manufacturer of dialysis machines, PD systems (HomeChoice), and dialyzer consumables. Vantive spin-off (2024) focuses on kidney care — a likely strategic acquirer or competitor for Qidni's home/portable dialysis positioning.

TypeDirect peer
Description

UK-based maker of Quanta Dialysis System, a small, portable hemodialysis device targeting home and clinic use. Directly comparable to Qidni's miniaturized dialysis machine thesis.

TypeEmerging player
Description

Singapore-based developer of a wearable peritoneal dialysis device. Comparable miniaturization thesis for portable dialysis, but on the PD rather than hemodialysis side.

TypeOthers
Description

Public-private partnership between HHS and ASN accelerating kidney care innovation (already a Qidni partner). Useful ecosystem reference rather than a direct competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qidni Labs

Medical Devices — Dialysis Equipmentqidni.life

Qidni Labs Inc. is a pre-commercial medical device company developing Qartridge™, a proprietary selective-absorption cartridge, and the Qidni/D portable dialysis machine that performs hemodialysis without dialysate, purified water, or grid power, targeting the global population of kidney failure patients without access to conventional dialysis infrastructure.

What Qidni Labs does

Qidni Labs Inc. is a privately held medical device company developing portable, infrastructure-independent hemodialysis technology. Founded in 2014 and headquartered across Buffalo, New York and Kitchener, Ontario, the company is led by founder and CEO Morteza Ahmadi and operates with fewer than 10 employees. Its stated objective is to address the up to 10 million kidney failure patients globally who lack access to dialysis, and its technology is targeted at rural populations, home dialysis candidates rejected due to inadequate water or electrical infrastructure, disaster response settings, satellite clinics, pandemic scenarios, and military or battlefield medical use.

The company's product platform is built around Qartridge™, a proprietary selective-absorption cartridge that removes uremic toxins and other solutes directly from whole blood, eliminating the need for the approximately 120 liters of dialysate and 300–500 liters of purified water required by conventional hemodialysis. The flagship device, Qidni/D, integrates this cartridge into one of the most miniaturized dialysis machines ever built, offering rechargeable battery operation, 3–4 hour treatment times comparable to standard hemodialysis, and cloud-based remote monitoring by the clinical team. Qartridge™ is positioned as a platform technology with stated optionality for selective removal of other solutes and biofluids beyond kidney applications.

Commercially, Qidni is pre-revenue: the company's own website states that Qidni devices and Qartridges are not approved by the US FDA or Health Canada and are not available for commercial sale. The intended revenue model combines hardware sales of the Qidni/D device, recurring revenue from single-use Qartridge™ consumables priced comparably to existing hemodialysis consumables, and licensing or partnership income from the underlying platform technology. The company has been financed through a mix of equity (SOSV/IndieBio, 43North, Sunhope Capital, ECO Angels/ECOAST Angels, China Canada Angel Alliance, Velocity) and non-dilutive capital (NRC IRAP, OBIO BDSP, L-SPARK, NATO DIANA), and is actively soliciting licensing and distribution partners as its primary go-to-market pathway.

Qidni Labs firmographics

Firmographics
Name
Qidni Labs
Legal name
Qidni Labs Inc.
Website
https://qidni.life
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Qidni Labs Inc. is a pre-commercial medical device company developing Qartridge™, a proprietary selective-absorption cartridge, and the Qidni/D portable dialysis machine that performs hemodialysis without dialysate, purified water, or grid power, targeting the global population of kidney failure patients without access to conventional dialysis infrastructure.
Ownership category
akta.pro rank

Qidni Labs industry classification

Industry
Product category
Medical Devices — Dialysis Equipment
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAKAA
Hemodialysis Machines & Systems
SECONDARYHLAHAKAH
Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges)
SECONDARYHLAHAKAG
Home Dialysis Equipment & Remote Monitoring

Keywords

  • Portable dialysis devices
  • Hemodialysis technology
  • Medical device cartridges
  • Kidney replacement therapy
  • Blood purification systems

Where Qidni Labs is headquartered

Location

Headquarters

HQ city
Buffalo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Qidni Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Qartridge™ Consumables: The Qartridge™ (Qidni cartridge) is a single-use disposable component for each dialysis session. Cost per treatment session is similar to current hemodialysis consumables cost. The company emphasizes they do not use expensive exotic materials in their cartridges.
  2. Qidni/D Device Sales: The Qidni/D flagship portable dialysis machine will be sold as a device. The company is pursuing licensing and partnership opportunities for distribution.
  3. Technology Licensing: The company is seeking licensing and partnership opportunities for their platform technology, which can be modified for applications beyond kidney dialysis for selective removal of target solutes from whole blood and other biofluids.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Qidni Labs product offering

Product offering

Core offering

Qidni Labs develops and plans to commercialize a portable, infrastructure-independent hemodialysis system comprising the Qidni/D miniaturized dialysis machine and the single-use Qartridge™ consumable. The system removes uremic toxins from whole blood without requiring dialysate, purified tap water, or AC power, enabling dialysis in rural areas, homes, disaster zones, battlefields, and satellite clinics while treatments are monitored remotely through a cloud-based clinical platform. The company is pre-commercial, pursuing FDA/Health Canada approval and actively seeking licensing and distribution partners.

Product overview

Qidni Labs offers a unified product portfolio centered on portable, accessible dialysis technology. The flagship product Qidni/D is a miniaturized dialysis machine that eliminates traditional infrastructure dependencies (no dialysate, no tap water, no electrical outlet required). This is powered by Qartridge™ technology, a proprietary selective blood purification cartridge that removes uremic toxins without the 120L of purified water needed in conventional hemodialysis. Together, these products enable dialysis in rural areas, disaster settings, military/battlefield environments, ambulances, satellite clinics, and homes where water and electricity infrastructure is unreliable or unavailable.

Differentiator

Problem solved

Functional benefit

Brands

  • Qartridge™: Proprietary platform technology providing high capacity for selective absorption and removal of uremic toxins and other solutes from large volumes of whole blood. The first application is in kidney blood dialysis.

Products and services

  • Qartridge™ Qartridge™ (Qidni cartridge) is a proprietary single-use disposable cartridge that provides high-capacity selective absorption and removal of uremic toxins and other solutes from large volumes of whole blood without requiring dialysate or large quantities of purified water. It is intended for use with the Qidni/D device to enable dialysis in settings where conventional water and dialysate infrastructure is unavailable, and the platform is also licensable for selective removal of target solutes from whole blood and other biofluids.
  • Qidni/D Qidni/D is a miniaturized, portable hemodialysis machine designed to function as a "dialysis clinic in a dialysis machine." It operates without dialysate, tap water, water purification systems, or AC power (can run on rechargeable batteries), delivers 3–4 hour treatment sessions comparable to existing hemodialysis, and is monitored remotely by the clinical team via a cloud-based system. It targets use in rural areas, homes, satellite clinics, ambulances, disaster response, and military/battlefield settings.

Quantifiable outcome

  • Water savings of 300-500L per treatment (equivalent to average person's daily water usage)
  • +2 more outcomes

Companies that use Qidni Labs

Customer profile

Segments7 records

Ideal customer profiles3 records

Qidni Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Qidni Labs partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • NATO-Ukraine Joint Analysis, Training and Education Centre (JATEC)coreStrategic or Co-development Partner · 17 February 2026JATEC selected Qidni Labs as one of nine companies to develop AI-based counter-drone solutions, medical systems, and autonomous defence technologies. JATEC is the first partner organization within NATO's structure with Ukraine holding equal status to member states. Based in Bydgoszcz, Poland.
  • NATO Allied Command Transformation / JATECcoreStrategic or Co-development Partner · 4 December 2025Qidni Labs won first place in NATO's 17th Innovation Challenge focused on battlefield medical innovation. Winners will advance toward rapid prototyping and field testing with Allied forces. NATO is prioritizing layered resilience and medical readiness adapted to drone surveillance, jamming, and extended evacuation delays.
  • OC Innovation (Ontario Centre of Innovation)minorStrategic or Co-development PartnerListed as a partner on Qidni Labs' Funding page. Ontario-based innovation organization supporting technology development.
  • National Research Council Canada (NRC)minorStrategic or Co-development PartnerListed as a partner on Qidni Labs' Funding page. Canadian government research organization supporting R&D.
  • Canada Space Agency (ASC-CSA)minorStrategic or Co-development PartnerListed as a partner on Qidni Labs' Funding page.
  • MaRS Discovery DistrictminorStrategic or Co-development PartnerListed as a partner on Qidni Labs' Funding page. Toronto-based innovation hub supporting startups.
  • L-SparkminorStrategic or Co-development PartnerListed as a partner on Qidni Labs' Funding page. Canadian accelerator for technology companies.
  • KidneyXminorStrategic or Co-development PartnerListed as a partner on Qidni Labs' Funding page. A public-private partnership to accelerate innovation in kidney care.
  • NSERC (Natural Sciences and Engineering Research Council of Canada)minorStrategic or Co-development PartnerListed as a partner on Qidni Labs' Funding page. Canadian federal research funding agency.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Qidni Labs competitors and assessment

Company assessment

Emerging players

  • Diality: US-based developer of a portable hemodialysis system for home and acute care settings. Competes in the same miniaturized hemodialysis category as Qidni/D.
  • AWAK Technologies: Singapore-based developer of a wearable peritoneal dialysis device. Comparable miniaturization thesis for portable dialysis, but on the PD rather than hemodialysis side.

Broad incumbents

  • Medtronic: Diversified medtech incumbent with renal care exposure and adjacent therapeutic apheresis technology. Relevant as a potential strategic acquirer given Qartridge's platform applicability beyond dialysis.
  • Fresenius Medical Care: Global leader in dialysis products and services (owns NxStage). Operates thousands of dialysis clinics and manufactures machines, dialyzers, and consumables — the dominant incumbent Qidni must eventually compete with or partner into.
  • NxStage Medical (Fresenius): Pioneer in home hemodialysis (NxStage System One), now owned by Fresenius. Most analogous precedent for portable home hemodialysis market entry — useful comparator for Qidni's regulatory and adoption trajectory.
  • DaVita: Largest US dialysis services provider operating thousands of outpatient clinics. Relevant for downstream channel access, payer relationships, and as a potential acquirer/licensor of portable dialysis innovations.
  • Baxter International (Vantive kidney care): Major manufacturer of dialysis machines, PD systems (HomeChoice), and dialyzer consumables. Vantive spin-off (2024) focuses on kidney care — a likely strategic acquirer or competitor for Qidni's home/portable dialysis positioning.

Direct peers

  • Outset Medical: Developer of Tablo, an FDA-cleared portable/home hemodialysis system with water purification and intuitive UX. Most directly comparable device competitor to Qidni/D in miniaturized dialysis for home and clinic settings.
  • Quanta Dialysis Technologies: UK-based maker of Quanta Dialysis System, a small, portable hemodialysis device targeting home and clinic use. Directly comparable to Qidni's miniaturized dialysis machine thesis.

Others

  • KidneyX: Public-private partnership between HHS and ASN accelerating kidney care innovation (already a Qidni partner). Useful ecosystem reference rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Qidni Labs social profiles

Digital presence

Qidni Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qidni Labs leadership team

Management profile

Number of profiles

Profiles1 record

Qidni Labs funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qidni Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qidni Labs

What does Qidni Labs do?

Qidni Labs develops and plans to commercialize a portable, infrastructure-independent hemodialysis system comprising the Qidni/D miniaturized dialysis machine and the single-use Qartridge™ consumable. The system removes uremic toxins from whole blood without requiring dialysate, purified tap water, or AC power, enabling dialysis in rural areas, homes, disaster zones, battlefields, and satellite clinics while treatments are monitored remotely through a cloud-based clinical platform. The company is pre-commercial, pursuing FDA/Health Canada approval and actively seeking licensing and distribution partners.

Is Qidni Labs a public or private company?

Qidni Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qidni Labs founded?

Qidni Labs was founded in 2014. It employs 11 to 50 people.

Where is Qidni Labs based?

Qidni Labs is headquartered in Buffalo, United States, in the North America region.

How does Qidni Labs make money?

Three revenue lines are on record. Qartridge™ Consumables are the primary driver. The others are qidni/D Device Sales and technology Licensing.

Who are Qidni Labs's main competitors?

Emerging players on record are Diality and AWAK Technologies. Broad incumbents are Medtronic, Fresenius Medical Care, NxStage Medical (Fresenius), DaVita and Baxter International (Vantive kidney care). Direct peers are Outset Medical and Quanta Dialysis Technologies. KidneyX is listed as an others.

Does Qidni Labs have an API?

No public API is recorded for Qidni Labs.

What industry is Qidni Labs in?

Qidni Labs's product category is Medical Devices — Dialysis Equipment. Its primary akta.pro industry code is HLAHAKAA, Hemodialysis Machines & Systems, with a secondary code of HLAHAKAH, Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges). Its NAICS code is 3391 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IndiebioQidni Labs Inc.Qidni Labs is developing implantable artificial kidneys for end-stage renal disease, using a QGel adsorbent that performs dialysis with 100 times less water. The company demonstrated viability on a fully nephrectomized sheep, which filtered out more urea than a typical clinic session. The technology aims to enable independent dialysis providers to serve millions without owning clinics.SosvQidni Labs Inc.Qidni Labs is developing artificial kidneys connected to the cloud to enable independent dialysis providers. Their QGel adsorbent performs dialysis with 100 times less water, and the company demonstrated viability on a nephrectomized sheep. The technology aims to reduce dialysis costs, which average $82,000 per patient per year in the US.ModAI solutions against Shahed drones, a ‘drone wall’, and autonomous defence systems – one year of JATECOn February 17, 2026, NATO and Ukraine marked one year since launching the NATO–Ukraine Joint Analysis, Training and Education Centre (JATEC) at its headquarters in Bydgoszcz, Poland, with the Centre establishing equal status for Ukraine alongside NATO member states. JATEC organised three NATO Innovation Challenges in 2025, selecting nine companies—including Alta Ares, Tytan, Atreyd, KMB Telematics Inc., Sentradel, DONS, Qidni Labs Inc., MonuMedical LLC, and Ixana—to develop AI-based counter-drone solutions, medical systems, and autonomous defence technologies. The Centre also facilitated Ukraine's participation in Article 5 exercises and coordinated interoperability initiatives between Ukrainian and NATO forces.NatoFrontline Medical Innovation: NATO’s 17th Innovation Challenge Advances Care in a Drone-Dominated BattlespaceNATO Allied Command Transformation, in partnership with the NATO-Ukraine Joint Analysis, Training and Education Centre (JATEC), concluded the 17th NATO Innovation Challenge focused on sustaining life and enabling safe casualty evacuation in drone-dominated battlespaces where the war in Ukraine has exposed critical medical gaps. Three winning teams were selected from an international field representing Canada, Norway, Sweden, the United States, Ukraine, the United Kingdom, and Finland: Qidni Labs Inc. (Canada) won first place for a portable battlefield renal replacement system, MonuMedical LLC (United States) placed second for a compact non-electric medication infuser, and Ixana (United States) placed third for a low-emission medical command and control system using body-confined electric fields. The winners will advance toward rapid prototyping and field testing with Allied forces as NATO prioritizes layered resilience and medical readiness adapted to drone surveillance, jamming, and extended evacuation delays.Healthcare IT Today5 Startups from MaRS Health Impact 2025 You Need to Know & Real Talk on Medical MisinformationAt MaRS Health Impact 2025, five medical device and digital health startups pitched, including Able Innovations, Aufero Medical, Qidni Labs, Ciba Health, and HeadFirst. A panel on medical misinformation highlighted that overconfidence, not lack of education, is the core problem, and trust depends on connection, not credentials.DIGITIMES AsiaRevolutionizing dialysis: Qidni Labs founder & CEO Morteza Ahmadi's quest to improve patient's quality of lifeQidni Labs, founded in 2014, is developing a portable, nearly waterless hemodialysis machine to address dialysis accessibility and affordability. The company notes 3.5 million patients on dialysis but 10 million lack access, and plans a Series A in Q1 2024 with team expansion to over 20.SecSEC FORM DQidni Labs Inc. filed a Notice of Exempt Offering of Securities with the SEC, detailing a total offering amount of $780,000. As of this filing, $730,000 has been sold, leaving $50,000 remaining to be sold, and the minimum investment accepted is $0 USD.QidniQidni Labs Received a Grant from OBIOQidni Labs received a grant from the Ontario Bioscience Innovation Organization (OBIO) through its Business Development Skill Program. The funding supports the commercialization of health science companies in Ontario.TechCrunchMobile dialysis startup eyes human trials in 2022 following encouraging animal studyQidni Labs, a Buffalo-based startup, is planning human trials in 2022 for its mobile dialysis device after an animal study in sheep showed it could reduce urea levels. The company has raised $1.5 million and aims to file for FDA approval by the second half of 2023.GooglePortable and wearable drug delivery systemA patent application discloses a portable wearable renal therapy system using a sorbent cartridge with a hydrogel to absorb toxins from blood or dialysate. The hydrogel can absorb 1-100 grams of urea per 24 hours and release therapeutic substances like insulin or EPO. The system aims to provide continuous dialysis with improved toxin clearance and reduced peritonitis risk.